Research Paper Volume 11, Issue 5 pp 1501—1509
Curcumin inhibits liver metastasis of gastric cancer through reducing circulating tumor cells
- 1 Department of Integrative Medicine, Zhongshan Hospital, University of Fudan, Shanghai 200032, China
- 2 Department of Interventional Therapy, Zhongshan Hospital, University of Fudan, Shanghai 200032, China
received: January 26, 2019 ; accepted: February 23, 2019 ; published: March 7, 2019 ;https://doi.org/10.18632/aging.101848
How to Cite
Copyright: Gu et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Primary gastric cancer (PGC) is the fourth most common malignant human cancer and the second leading cause of death worldwide. The majority of the subjects of PGC is diagnosed at a late stage, resulting in poor prognosis and therapeutic outcome, largely attributable to dissemination of tumor cells into circulation as circulating tumor cells (CTCs) and their formation of distal tumor. Curcumin is an active ingredient from the rhizome of the plant Curcuma longa. Here, we assessed whether treatment with Curcumin may reduce the incidence of metastatic tumor formation in liver in mice carrying PGC. We found that Curcumin treatment significantly reduced the presence of CTCs and formation of liver tumor. Mechanistically, Curcumin reduced CXCR4 expression in PGCs in vitro and in vivo, and thus likely inhibited metastasis of PGC through suppression of stromal cell -derived factor-1/CXCR4 signaling. Thus, our study suggests that Curcumin may inhibit liver metastasis of PGC through reducing CTCs.